Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

2.

Infection Burden High With Myeloma T-Cell Therapies

3.

Capivasertib Wins Metastatic Prostate Cancer Approval

4.

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

5.

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot